Lefamulin Rivals Moxifloxacin in Treating Community-Acquired Bacterial Pneumonia: Evidence from a Randomized Trial | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Articles in Press, Accepted Manuscript, Available Online from 03 August 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2025.375274.2515 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohammed Al-Qatan  1; Khansaa Fadhil2; Fanar Mahmood3
| ||||
| 1Department of Biology, College of Science, University of Mosul, Mosul, Iraq | ||||
| 21Northern technical university ,Al-dour technical institute, Department of Technical medical laboratory | ||||
| 3Nineveh Education Directorate, Mosul, Iraq | ||||
| Abstract | ||||
| Background: Lefamulin is a new pleuromutilin antibiotic that demonstrates effectiveness comparable to moxifloxacin in treating community-acquired bacterial pneumonia (CABP). It targets various pathogens, and can be administered both orally and intravenously. Our prospective randomized clinical trial aimed to assess the clinical effectiveness and tolerability of Lefamulin (150 mg IV every 12 hours) versus Moxifloxacin (400 mg daily) in patients with CABP classified as PSI class III or higher. Materials and methods: This study investigated 150 adult bacterial CABP patients divided into two groups. Compared intravenous Lefamulin (150mg every 12h) to oral (600mg every 12h, for 5 days) against intravenous moxifloxacin (400mg every 24h) to oral (400mg every 24h, for 7 days). Patients' PSI and CURB-65 scores were determined, and causal organisms identified. Effectiveness and safety were assessed via follow-ups at weeks 2 and 4, focusing on PSI risk classes II-IV and CURB-65. Results: Preliminary results showed that the two study groups were similar in demographic and baseline characteristics, such as systemic inflammation, and a similar distribution of bacterial pathogens. The results also showed a comparable clinical response profile between the two groups after the two treatment periods. Patients in both groups were not free of clinical complications and adverse effects, albeit at slightly varying rates. Conclusion: This research concluded that lefamulin is non-inferior to moxifloxacin in terms of effectiveness and exhibits a favorable tolerability profile for the treatment of community-acquired bacterial pneumonia (CABP), a benefit particularly noted in more severe cases (classified as PSI class III or higher. | ||||
| Keywords | ||||
| Lefamulin; Moxifloxacin; antibiotic; bacteremia; “Community-Acquired Bacterial Pneumonia | ||||
|
Statistics Article View: 44 |
||||
